Observations placeholder

Methamphetamine [crystal meth]

Identifier

005758

Type of Spiritual Experience

Hallucination

Number of hallucinations: 111

Background

 

 

A description of the experience

Methamphetamine  - metamfetamine, methylamphetamine, N-methylamphetamine, desoxyephedrine, and "meth" – is an amphetamine said to produce [and I quote] “alertness, concentration, energy, and in high doses, euphoria, self-esteem, and increased libido” and if you believe that, you’ll believe anything.  In general, as you will see from the papers below, the main side effect is brain damage and permanent psychosis.

On Jan, 27, 2017 582 people reported to have side effects when taking Methamphetamine Hydrochloride.  Among them, 4 people (0.69%) have Hallucination

It works as a releasing agent on - dopamine, norepinephrine and serotonin. Quite extraordinarily, Methamphetamine is “FDA approved for the treatment of ADHD and exogenous obesity” and marketed in the USA under the trademark name Desoxyn [see separate entry].

Methamphetamine is illegally synthesized and then sold in a crystalline form as "crystal meth". People who use any form can experience [unsurprisingly] very severe withdrawal symptoms lasting some time when they experience depression, fatigue, excessive sleeping and an increased appetite. “Chronic methamphetamine abuse may result in prolonged psychiatric disorders, cognitive impairment, as well as an increased risk of developing Parkinson's disease

For EROWID entry see LINK

Dale Pendell in his wonderful book Pharmakodynamis had a rather poor opinion of the effects of amphetamine and methamphetamine saying the people who had taken them have “a boorish overpowering presence. Talking more than listening. Starting ten jobs and finishing none of them. A trail of chaos. Sweating. A distinctive meth ‘smell’ or ‘vibe’ palpably apparent to everyone else in the room”. I am told that many in the financial services industry and other so called high powered jobs – property developers, politicians, marketing people, people developing nuclear power plants etc are extensive users of amphetamines.

****************************************************************

J Contemp Dent Pract. 2010 Jan 1;11(1):E073-80.

Oral manifestations of "meth mouth": a case report.

Turkyilmaz I1.

AIM:  The aim of the documentation of this clinical case is to make clinicians aware of "meth mouth" and the medical risks associated with this serious condition.

BACKGROUND:  Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior. Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear. Oral rehabilitation of patients using methamphetamine can be challenging.

CASE DESCRIPTION:  A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics. A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult. She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.

SUMMARY:  The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of "meth mouth." Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.

CLINICAL SIGNIFICANCE:  This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines. Dental practitioners also may be skeptical about the reliability of appointment keeping by these patients, as they frequently miss their appointments without reasonable justification.

PMID: 20098969

 ***********************************************************

Drug Alcohol Depend. 2015 Mar 1;148:158-64. doi: 10.1016/j.drugalcdep.2014.12.035. Epub 2015 Jan 13.  Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.  Chen CK1, Lin SK2, Chen YC1, Huang MC3, Chen TT4, Ree SC1, Wang LJ5.

BACKGROUND: Prolonged exposure to methamphetamine (meth) has neurotoxic effects and impairs neurocognitive functions. This study aims to ascertain whether meth users who experience persistent psychosis suffer more severe cognitive impairment than those not experiencing persistent psychosis.

METHODS:  This cross-sectional study includes 252 participants: 25 meth users without psychosis (METH-P), 50 with brief psychosis (METH+BP), and 56 with persistent psychosis (METH+PP), as well as 54 patients with schizophrenia and 67 healthy controls. The neurocognitive function and clinical psychopathology of each patient were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Brief Psychiatric Rating Scale (BPRS), respectively.

RESULTS:  All cognitive domains evaluated with BACS (verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, executive function, and composite scores) in METH+PP patients were similar to those in the schizophrenia patients and were worse than those in METH-P, METH+BP, and the healthy control subjects. Furthermore, cognitive functioning in meth users that did not experience persistent psychosis showed no statistically significant difference compared with the healthy control subjects. Among the meth users in this study, the negative symptom scores in the BPRS correlated to cognitive performance on the BACS, with the exception of motor speed.

CONCLUSIONS:  Meth users display heterogeneity in their psychotic symptoms and cognitive profiles. Therefore, persistent psychotic symptoms may denote a risk for cognitive decline among meth users. Further longitudinal studies should be performed in the future to clarify the causal relationship between cognitive deficits and the development of persistent psychosis.

PMID:  25601645

The source of the experience

eHealthme

Concepts, symbols and science items

Concepts

Symbols

Science Items

Activities and commonsteps

Commonsteps

References